Articles tagged with B Lymphocytes
A recent clinical trial found that gene therapy can insert the correct ADA gene into patient bone marrow cells, leading to a good response. Defects in B cell tolerance are also corrected after gene therapy, supporting its use as an effective treatment option for ADA-deficient severe combined immunodeficiency patients.
Researchers have discovered a CD19-dependent pathway that contributes to the growth of B cell lymphomas. High levels of CD19 correlate with increased MYC activity, suggesting a new target for therapies currently in clinical trials.
Researchers identified a rare immune cell's role in antibody production and 'memory' of infectious agents, crucial for vaccine development and potential treatment of immune disorders. T follicular helper cells can remember past infections, enabling rapid responses to future attacks.
A new study challenges the long-held theory that antibodies are essential for antiviral immunity. Researchers found that mice infected with the vesicular stomatitis virus (VSV) could survive even without producing antibodies, as their B cells produced a chemical that maintained innate immune cells called macrophages.
Research team led by Edward T. H. Yeh discovers that SENP1 regulates SUMOylation of STAT5, essential for lymphoid development of T and B cells. Without SENP1, STAT5 cannot be activated or recycled, leading to severe defects in immune cell development.
Researchers have discovered a novel B cell that produces the growth factor GM-CSF, which stimulates other immune cells and helps protect against sepsis. The newly identified B cells, called innate response activator (IRA) B cells, may play a critical role in striking a balance between controlling infection and inflammation.
A recent study by the Walter and Eliza Hall Institute found that B cells can have multiple fates, including death, division, antibody production, or changes in antibody type. The researchers proposed that cell fates are determined by internal processes rather than external cues.
Researchers discovered neutrophils exist in the spleen without an infection, contributing new knowledge to biology. These cells have an immunoregulating role, interacting with B lymphocytes to produce antibodies.
Researchers at Penn Medicine discovered that B cells can produce unequal daughter cells through a process involving helper T cells and specific proteins. This finding may explain how lifelong antibodies are generated after vaccination, and could also shed light on the development of cancerous blood cells like leukemia.
Researchers at the Trudeau Institute have discovered a new properties of a potential vaccine adjuvant that suggests it could be useful for enhancing protection against a number of different infections. The discovery provides a promising lead for developing a new class of vaccines.
Researchers discovered that intestinal B cells acquire functions allowing them to neutralize pathogens while in the gut, a complex balance between beneficial and harmful bacteria. This finding provides insight into the immune system's ability to fight infection without damaging beneficial bacteria and other essential cells.
Researchers have discovered the FBXO11 gene as a novel tumor suppressor in B-cells, which regulates BCL6 protein levels. Deletions or mutations of FBXO11 contribute to DLBCL's development, with reconstitution of its expression inhibiting proliferation and inducing cell death.
Researchers have identified a non-classical form of fetal immune thrombocytopenia that can lead to miscarriage and habitual abortion. The condition is characterized by excessive platelet activation and blood clot formation in the placenta. New treatments targeting this condition have been suggested, offering hope for women affected by it.
A new study suggests that Rituximab treatment can lead to significant improvement in CFS symptoms, potentially revealing a new direction for CFS research. The anti-CD20 antibody depletes B-lymphocytes, which are thought to be crucial in the disease's progression.
Researchers at The Wistar Institute have discovered protein signals responsible for preserving anti-viral antibody memory. The study highlights how BLyS and APRIL sustain cells that produce antibodies against viruses, crucial knowledge for vaccine development.
Researchers have demonstrated a new HIV vaccine approach by designing an altered form of the virus's outer coating protein. This allows for better targeting of immature B cell receptors, leading to enhanced immune responses in animal models.
Research suggests that blood stem cells may play a role in the development of chronic lymphocytic leukemia (CLL), a cancer of mature white blood cells. CLL often begins with an asymptomatic proliferation of B cells called monoclonal B lymphocytosis (MBL). The study found that hematopoietic stem cells, which can give rise to any type of...
Researchers developed a new method to assess CNS drug action using eye movements in mice, which showed promise for treating diseases such as Huntington's disease. Additionally, studies revealed that the protein GSK-3 is critical for lithium's effects on behavior in bipolar disorder patients.
A team of researchers at National Jewish Health discovered a type of B cell that may contribute to autoimmune disease, particularly in women. These cells produce autoantibodies and are more prevalent in elderly female mice, young and old mice prone to autoimmune disease, and humans with autoimmune diseases.
Researchers have been awarded grants to develop innovative therapies for pulmonary fibrosis, autoimmune disease, cancer, and arthritis. The projects include a joint aspirate facilitator device and novel compounds for Pseudomonas biofilm disruption.
A team from the University of Sheffield has discovered a novel mechanism that potentially accounts for the development of many different types of lymphoma. The research found that B-cells are deficient in one of the main DNA repair pathways, which explains why strong UV exposure is a major environmental risk factor for the disease.
Researchers have discovered that cancer cells use specific chemokines to create a survival niche in the lymph nodes and spleen, allowing them to grow and develop. This niche is created by the interaction between cancer cells and stromal cells, which secrete increased quantities of chemokines CCL19/CCL21.
Researchers at NIH have demonstrated how to reactivate immune cells exhausted by chronic HIV using siRNA-based approach. This breakthrough may lead to improved human antibody responses against HIV and other pathogens.
A study published in Science Express reveals that RNA sequences in human cells diverge from DNA sequences, generating proteins with different sequences. The findings suggest unknown cellular processes are acting on RNA to create genetic diversity, which may contribute to differences in disease susceptibility.
A new experimental drug, PCI-32765, has shown promising results in selectively targeting and killing malignant B cells in chronic lymphocytic leukemia (CLL) patients. By inhibiting key signaling molecules and promoting apoptosis, the agent reduces the risk of life-threatening infections associated with current CLL therapies.
Research at RIKEN Research Center for Allergy and Immunology reveals ERK signaling pathway's role in B cell differentiation into antibody-producing plasma cells. The finding could lead to breakthroughs in drug discovery for autoimmune diseases and allergies.
Researchers have identified a distinct population of immune cells that contribute to the pathogenesis of type 1 diabetes by helping CD8+ T cells elicit autoimmune responses in the pancreas. This subset of CD4+ T cells produces IL-21 and express CCR9, playing a critical role in autoimmune disease.
University of Iowa researchers identify TRAF6 as essential for LMP1 functions, which can be targeted to develop new therapies for B cell lymphomas and autoimmune diseases. The discovery may lead to the development of novel treatments that mimic CD40 activation while avoiding disruptions in normal immune function.
A study published in The Journal of Immunology reveals that the elderly are more susceptible to pneumonia and bacterial infections due to a decline in immune system cells. Researchers have found that macrophages and B cells, which fight bacteria, appear effective but are fewer in number, making them less effective. Developing targeted ...
Ohio State University researchers have discovered a way to manipulate the immune response to vaccination, enabling effective immunization even when maternal antibodies are present. By using a specific type of antibody, known as IgM, they can activate B cells and stimulate an immune response, potentially improving childhood vaccination ...
Primitive lampreys have structures within their gills that play a role similar to the thymus, where T cells develop in mammals and birds. The finding suggests two separate organs for immune cell development preceded the appearance of key features like antibodies and T cell receptors.
A Ph.D. student at Université du Québec à Montréal has identified a gene that may facilitate the diagnosis of B-cell acute lymphocytic leukemia, mostly affecting children. The Fmn2 gene shows abnormal activity in both mouse and human cells with this disease.
Research highlights the key role of estrogen signaling in maintaining energy balance, as well as the propagation of α-synuclein in Parkinson's disease. Additionally, a new immune cell activator has been identified to protect mice from tumors through an IFN-gamma-independent mechanism.
A team of IRCM researchers identified a new regulator, Miz-1, essential for the proper development and maturation of B cells. The discovery highlights the importance of the IL-7 signaling pathway for B-cell survival and maturation.
A new study finds that dendritic cells play a key role in amplifying autoimmune disease, specifically systemic lupus erythematosus (SLE). The research suggests that depleting dendritic cells may be a potential therapeutic strategy for treating SLE and potentially other autoimmune diseases.
Researchers at Duke University Medical Center have identified a major pathway that infected cells use to root out Epstein-Barr virus infections, which can cause cancer in people with compromised immune systems. The study found that two enzymes play a critical role in mediating this response and preventing unchecked cell growth.
Researchers found plasma cells regulate immune response by negatively impacting follicular helper T cells. The discovery has implications for vaccine administration and autoimmunity.
A new mutation in the B cell activating factor receptor (BAFF-R) has been identified as a potential contributor to non-Hodgkin's lymphoma. The mutation amplifies BAFF signaling, leading to increased B cell function and cancer progression.
A new study finds that SHIP and PTEN proteins act cooperatively to suppress B cell lymphoma. The research could lead to the development of new anti-lymphoma drugs targeting PI3K signaling.
Researchers discover that CD4+ T cells release interleukin-21, instructing B cells to produce antibodies targeting helminth-derived products. This signaling pathway is specific to worm infections and may hold key to treating diseases like asthma and allergies.
B-cell receptors form ordered oligomer complexes that only become active when binding partners disintegrate into subunits. This new model challenges the accepted scientific doctrine and may contribute to the development of new vaccination strategies and treatments for B-cell tumours.
Dana-Farber Cancer Institute scientists have identified cells in mice that prevent the immune system from attacking own cells, potentially leading to improved therapies for autoimmune diseases. The discovery highlights the importance of balancing the immune response, with CD8+ Treg cells playing a key role.
Researchers at Ohio State University Comprehensive Cancer Center have identified a targeted agent that promotes cell death and disrupts survival pathways in CLL cells. The agent blocks PI3K-delta, an isomer of the PI3K pathway required for hematopoietic cell functions.
Researchers have identified Gαq as a key protein that determines the fate of damaging cells, leading to autoimmune disorders like arthritis. The discovery offers new hope for treatments and personalized therapy for patients.
A University of Rochester scientist has discovered a new approach to boosting the body's response to vaccinations using insulin-sensitizing drugs. This breakthrough could lead to improved vaccine efficacy for individuals with weakened immune systems, such as infants and elderly people.
A molecule that binds toll-like receptors doubles the early antibody response to an antigen and shifts it to a more effective IgG form. The findings support bridge immunity, which links innate and adaptive arms of the immune response.
Researchers found that antibody-producing B cells contribute to atherosclerosis in mice, while eliminating them could prevent the disease through increased production of immune protein interleukin-17. This discovery suggests that B cell-depleting drugs may also reduce the risk of atherosclerosis.
Researchers at Catholic University of Rome have developed a promising new therapy against systemic sclerosis (scleroderma), an autoimmune disease characterized by skin hardening and organ dysfunction. The treatment targets the immune system's B-cells, reducing side effects associated with traditional immunosuppressive therapies.
Researchers have identified a unique gene pattern in white blood cells of tolerant kidney transplant recipients, which may enable them to stop taking immunosuppressive drugs. The study found that B cell genes play a crucial role in maintaining tolerance to transplanted organs.
Researchers at Medical College of Georgia have identified a rare hybrid cell that can switch the immune system on or off, expressing indoleamine 2,3 dioxygenase to turn off T cells. This unique cell has properties of both dendritic and B cells, with potential implications for cancer and rheumatoid arthritis therapies.
Researchers at Genentech Inc. developed a way to specifically eliminate IgE-producing B cells, providing a new approach to treating asthma and other allergic diseases. The monoclonal antibody neutralizes the effects of soluble IgE molecules in the blood, reducing their levels and numbers.
A team of researchers at Karolinska Institutet has discovered a crucial role for NKT cells in regulating B cell activation and preventing autoimmunity. This finding provides new insights into the mechanisms underlying autoimmune diseases, such as MS and rheumatoid arthritis.
Immunologist Roberta Pelanda and her team found that immature B cells require a positive signal from the B-cell receptor to mature and enter the spleen. Protein Erk helps deliver this signal, enabling B cells to escape the bone marrow and contribute to immune defense.
A new study reveals that resident dendritic cells capture and present flu viruses to B-lymphocytes, activating an immune response. Harnessing this function could lead to more effective vaccines.
Researchers at Helmholtz Munich identify the BZLF1 protein as a crucial factor in EBV's life cycle, enabling viral activation and gene expression. The study reveals a novel mechanism for virus detection and reactivation, providing insights into EBV's role in tumor growth.
Researchers have found that CD20 protein is essential for generating optimal B cell immune responses, particularly to T-independent antigens. The discovery was made by analyzing a patient with a mutation in the CD20 gene, who had impaired B cell responses and recurrent infections.
Researchers discover CD20's nonredundant role in generating optimal B cell immune responses. Gene therapy approach targets alpha-1 antitrypsin to alleviate emphysema symptoms. Inhibiting fatty acid oxidation sensitizes leukemic cells to death-inducing compounds.
Researchers found that the immune system produces early-stage B cells with potent HIV-blocking antibodies but eliminates them before they mature. This 'catch-22' prevents the production of these protective antibodies, hindering vaccine development.
Researchers at Boston Children's Hospital have discovered a gene enhancer responsible for activating cancer-causing genes in B cells, leading to the development of a new target for lymphoma therapy. The study suggests that targeting this regulatory component could potentially arrest lymphomas and other blood-related cancers.
Researchers found that injections of rituximab slowed beta cell destruction in patients with newly diagnosed type 1 diabetes, suggesting a potential treatment option. The study suggests targeting B cells may improve beta-cell function in early type 1 diabetes.